- Home
- OPT vs PRTA Comparison
OPT vs PRTA Comparison
Compare OPT & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- PRTA
- Stock Information
- Founded
- OPT 1984
- PRTA 2012
- Country
- OPT Australia
- PRTA Ireland
- Employees
- OPT N/A
- PRTA N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- OPT Health Care
- PRTA Health Care
- Exchange
- OPT Nasdaq
- PRTA Nasdaq
- Market Cap
- OPT 574.0M
- PRTA 643.0M
- IPO Year
- OPT 2020
- PRTA N/A
- Fundamental
- Price
- OPT $3.90
- PRTA $13.77
- Analyst Decision
- OPT Strong Buy
- PRTA Buy
- Analyst Count
- OPT 1
- PRTA 7
- Target Price
- OPT $12.00
- PRTA $46.50
- AVG Volume (30 Days)
- OPT 18.3K
- PRTA 711.1K
- Earning Date
- OPT 02-26-2025
- PRTA 02-13-2025
- Dividend Yield
- OPT N/A
- PRTA N/A
- EPS Growth
- OPT N/A
- PRTA N/A
- EPS
- OPT N/A
- PRTA N/A
- Revenue
- OPT $261,859.00
- PRTA $133,350,000.00
- Revenue This Year
- OPT N/A
- PRTA $56.89
- Revenue Next Year
- OPT $46,864.26
- PRTA N/A
- P/E Ratio
- OPT N/A
- PRTA N/A
- Revenue Growth
- OPT N/A
- PRTA N/A
- 52 Week Low
- OPT $1.79
- PRTA $11.70
- 52 Week High
- OPT $5.45
- PRTA $34.75
- Technical
- Relative Strength Index (RSI)
- OPT 56.41
- PRTA 48.19
- Support Level
- OPT $3.59
- PRTA $12.39
- Resistance Level
- OPT $3.90
- PRTA $13.64
- Average True Range (ATR)
- OPT 0.24
- PRTA 1.03
- MACD
- OPT 0.02
- PRTA -0.02
- Stochastic Oscillator
- OPT 74.11
- PRTA 40.47
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).